As of 2026-03-29, the EV/EBITDA ratio of Syros Pharmaceuticals Inc (SYRS) is 0.18. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SYRS's latest enterprise value is -17.19 mil USD. SYRS's TTM EBITDA according to its financial statements is -95.71 mil USD. Dividing these 2 quantities gives us the above SYRS EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.1x - 14.0x | 13.9x |
| Forward P/E multiples | 13.7x - 18.1x | 15.8x |
| Fair Price | (28,264.76) - (28,933.73) | (30,668.87) |
| Upside | -24116788.4% - -24687582.3% | -26168078.9% |
| Date | EV/EBITDA |
| 2026-03-20 | 0.18 |
| 2026-03-19 | 0.18 |
| 2026-03-18 | 0.18 |
| 2026-03-17 | 0.18 |
| 2026-03-16 | 0.18 |
| 2026-03-13 | 0.18 |
| 2026-03-12 | 0.18 |
| 2026-03-11 | 0.18 |
| 2026-03-10 | 0.18 |
| 2026-03-09 | 0.18 |
| 2026-03-06 | 0.18 |
| 2026-03-05 | 0.18 |
| 2026-03-04 | 0.18 |
| 2026-03-03 | 0.18 |
| 2026-03-02 | 0.18 |
| 2026-02-27 | 0.18 |
| 2026-02-26 | 0.18 |
| 2026-02-25 | 0.18 |
| 2026-02-24 | 0.18 |
| 2026-02-23 | 0.18 |
| 2026-02-20 | 0.18 |
| 2026-02-19 | 0.18 |
| 2026-02-18 | 0.18 |
| 2026-02-17 | 0.18 |
| 2026-02-13 | 0.18 |
| 2026-02-12 | 0.18 |
| 2026-02-11 | 0.18 |
| 2026-02-10 | 0.18 |
| 2026-02-09 | 0.18 |
| 2026-02-06 | 0.18 |
| 2026-02-05 | 0.18 |
| 2026-02-04 | 0.18 |
| 2026-02-03 | 0.18 |
| 2026-02-02 | 0.18 |
| 2026-01-30 | 0.18 |
| 2026-01-29 | 0.18 |
| 2026-01-28 | 0.18 |
| 2026-01-27 | 0.18 |
| 2026-01-26 | 0.18 |
| 2026-01-23 | 0.18 |
| 2026-01-22 | 0.18 |
| 2026-01-21 | 0.18 |
| 2026-01-20 | 0.18 |
| 2026-01-16 | 0.18 |
| 2026-01-15 | 0.18 |
| 2026-01-14 | 0.18 |
| 2026-01-13 | 0.18 |
| 2026-01-12 | 0.18 |
| 2026-01-09 | 0.18 |
| 2026-01-08 | 0.18 |